SCHEMBL4299985

SCHEMBL4299985

CC(C)(C)OC(=O)N[C@@H](CO)Cc1ccc(C(F)(F)F)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.45
TRPV3 Q8NET8 3/20 0.39
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
KCNQ4 P56696 1/20 0.39
KCNQ5 Q9NR82 1/20 0.39
CTSS P25774 2/20 0.39
CTSK P43235 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
CYP3A4 P08684 5/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
APP P05067 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
PPARD Q03181 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2549982 1.00 ATM (0.45) ATMTRPV3KCNQ3KCNQ2KCNQ4
SCHEMBL2549984 1.00 ATM (0.45) ATMTRPV3KCNQ3KCNQ2KCNQ4
SCHEMBL2541280 0.93 ATM (0.45) ATMCTSSCTSKPPARGPPARA
SCHEMBL2541282 0.93 ATM (0.45) ATMCTSSCTSKPPARGPPARA
SCHEMBL1742124 0.86 ATM (0.41) ATMKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL1742125 0.86 ATM (0.41) ATMKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL1519761 0.85 ATM (0.40) ATMKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL1519764 0.85 ATM (0.40) ATMKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL1595321 0.84 ATM (0.40) ATMKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL13285668 0.84 ATM (0.40) ATMKCNQ3KCNQ2KCNQ4KCNQ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 ATM 140/4885TRPV3 2805/4885KCNQ3 4017/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 ATM 315/4885TRPV3 2215/4885KCNQ3 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.